Development and validation of a stability-indicating RP-LC method for the determination of sitagliptin and simvastatin in the presence of their degradation products in bulk drug mixture and combined pharmaceutical preparations

Document Type


Publication Date



A simple, selective, and precise stability-indicating reversed-phase liquid chromatographic method has been developed and validated for the determination of the first Food and Drug Administration (FDA) approved fixed-dose combination for both diabetes type II and high cholesterol; sitagliptin phosphate monohydrate (SIT); and simvastatin (SIM) in the presence of acid and alkali degradation products of SIT, and the hydrolytic degradation product of SIM. The method was based on gradient elution on a reversed phase C8 column (250mm×4.6mm, 5 μm)-Zorbax SB using a mobile phase consisting of 0.01M potassium dihydrogen orthophosphate (pH=2.6) and acetonitrile. Quantitation was achieved using UV detection at 210nm for SIT and its degradation products, while quantitation of SIM and its degradation product was achieved using UV detection at 240nm. Linearity, accuracy, and precision were found to be acceptable over the concentration ranges of 0.5-200μ g mL-1 and 0.5-100 μ g mL -1 for SIT and SIM, respectively. Limits of detection and quantitation for SIT were found to be 5.65ng and 17.12ng, respectively, while for SIM were found to be 2.72ng and 8.25ng, respectively. The proposed method was successfully applied to the determination of the cited drugs in bulk and in their combined pharmaceutical preparations. © 2014 Copyright Taylor & Francis Group, LLC.

This document is currently not available here.